Literature DB >> 16126981

Humoral antigenic targets of the ribosomal P0 lupus autoantigen are not limited to the carboxyl region.

Benjamin F Bruner1, Donny M Wynn, Morris Reichlin, John B Harley, Judith A James.   

Abstract

Autoantibodies binding the ribosomal P phosphoproteins are highly specific for systemic lupus erythematosus (SLE) and can be found in precipitating levels in approximately 15% of these patients. Anti-ribosomal P antibodies are directed against three proteins, and the primary autoimmune target of this response has been described as a common 22-amino acid sequence. Sera from 31 anti-ribosomal P immunodiffusion-positive SLE patients were tested for C-terminal P-peptide reactivity by ELISA. Sera from three patients (9.7%) were negative for the peptide ELISA, despite having anti-ribosomal P by immunodiffusion and Western blot. In addition, inhibition experiments showed that the common P-peptide response accounts for a variable amount of anti-ribosomal P0 reactivity (52-89% of the response dependent upon the patient serum). Based upon these findings, fine-specificity sequential humoral epitope mapping of ribosomal P0 was performed. Several common sequential antigenic targets were defined dispersed throughout the molecule. The most commonly targeted epitopes included RDMLLANKVPAAARA (amino acids 99-113, 11 of 12 patients reactive) and QALGITTKISRGT (amino acids 139-151, 9 of 12 patients reactive). This study confirms that the P22 ribosomal peptide is commonly targeted in SLE and accounts for a variable percentage of the anti-ribosomal P response. Additional anti-ribosomal P humoral epitopes are described.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126981     DOI: 10.1196/annals.1361.081

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides.

Authors:  Latisha D Heinlen; Lauren L Ritterhouse; Micah T McClain; Michael P Keith; Barbara R Neas; John B Harley; Judith A James
Journal:  J Mol Med (Berl)       Date:  2010-04-17       Impact factor: 4.599

2.  Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope.

Authors:  M Mahler; N Agmon-Levin; M van Liempt; Y Shoenfeld; A Waka; F Hiepe; A Swart; I Gürtler; M J Fritzler
Journal:  Rheumatol Int       Date:  2010-12-08       Impact factor: 2.631

3.  Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features.

Authors:  Sherry R Crowe; Joan T Merrill; Evan S Vista; Amy B Dedeke; David M Thompson; Scott Stewart; Joel M Guthridge; Timothy B Niewold; Beverly S Franek; Gillian M Air; Linda F Thompson; Judith A James
Journal:  Arthritis Rheum       Date:  2011-08

4.  Diverse humoral autoimmunity to the ribosomal P proteins in systemic lupus erythematosus and hepatitis C virus infection.

Authors:  K Kessenbrock; M J Fritzler; M Groves; P Eissfeller; C A von Mühlen; P Höpfl; M Mahler
Journal:  J Mol Med (Berl)       Date:  2007-08-01       Impact factor: 4.599

5.  Lupus anti-ribosomal P autoantibody proteomes express convergent biclonal signatures.

Authors:  M A Al Kindi; A D Colella; D Beroukas; T K Chataway; T P Gordon
Journal:  Clin Exp Immunol       Date:  2016-01-29       Impact factor: 4.330

6.  Expression, tissue localization and serodiagnostic potential of Taenia multiceps acidic ribosomal protein P2.

Authors:  Xing Huang; Lin Chen; Yingdong Yang; Xiaobin Gu; Yu Wang; Weimin Lai; Xuerong Peng; Guangyou Yang
Journal:  Parasit Vectors       Date:  2015-12-01       Impact factor: 3.876

7.  Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies.

Authors:  Michael Mahler; Jennifer T Ngo; Johannes Schulte-Pelkum; Tanja Luettich; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2008-11-11       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.